Iovance Biotherapeutics, Inc. develops and commercializes novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Company news commonly addresses Amtagvi, described by Iovance as the first FDA-approved T cell therapy for a solid tumor indication, Proleukin, lifileucel, and pipeline work across solid tumor cancers.
Recurring updates include clinical data, regulatory disclosures, operating and financial results, corporate presentations, material agreements, and governance matters. Iovance also reports Nasdaq inducement equity grants under its Amended and Restated 2021 Inducement Plan as part of its public-company compensation disclosures.
Iovance Biotherapeutics (NASDAQ: IOVA) announced new interim data from Cohort 2 of the C-144-01 study of lifileucel for advanced melanoma, to be presented at ASCO 2020. As of February 2020, the median duration of response (DOR) remains unmeasured at a median follow-up of 17 months, with an overall response rate of 36.4% from 66 patients. The adverse event profile aligns with advanced disease and treatment regimens. The presentation will provide further insights into the durable effects of TIL therapy in heavily pretreated patients. Future updates are anticipated following the ASCO event.
Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 2020 results, posting a net loss of $69.6 million, or $0.55 per share, up from a net loss of $37.0 million, or $0.30 per share in Q1 2019. R&D expenses surged to $57.0 million due to increased clinical trials and licensing costs. The company held $251.2 million in cash at March 31, 2020. Iovance remains committed to commercializing TIL therapies for melanoma and cervical cancer, with pivotal study enrollments progressing ahead of schedule, and plans for a BLA submission in late 2020.
Summary not available.
Summary not available.